These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15704523)

  • 1. Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
    Conti CR
    Clin Cardiol; 2005 Jan; 28(1):1-2. PubMed ID: 15704523
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
    MMW Fortschr Med; 2005 Jul; 147(27-28):44. PubMed ID: 16041942
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
    Verma A; Solomon SD
    Curr Heart Fail Rep; 2007 Dec; 4(4):183-9. PubMed ID: 18221614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
    Doggrell S
    Expert Opin Pharmacother; 2003 Sep; 4(9):1605-7. PubMed ID: 12943490
    [No Abstract]   [Full Text] [Related]  

  • 5. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM; Plosker GL
    Drugs; 2004; 64(23):2689-707. PubMed ID: 15537370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone in patients with left ventricular dysfunction.
    Aggarwal A
    N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9. PubMed ID: 12840098
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
    Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 9. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone in patients with left ventricular dysfunction.
    Coca SG; Buller GK
    N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9. PubMed ID: 12846223
    [No Abstract]   [Full Text] [Related]  

  • 12. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 13. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapy update. Inspra (eplerenone tablets).
    Kloner RA
    Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
    [No Abstract]   [Full Text] [Related]  

  • 15. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 16. Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?
    Conti CR
    Clin Cardiol; 2005 Aug; 28(8):360-1. PubMed ID: 16144210
    [No Abstract]   [Full Text] [Related]  

  • 17. Aldosterone blockade and heart failure.
    Jessup M
    N Engl J Med; 2003 Apr; 348(14):1380-2. PubMed ID: 12668698
    [No Abstract]   [Full Text] [Related]  

  • 18. Aldosterone blockade in post-acute myocardial infarction heart failure.
    Pitt B; Ferrari R; Gheorghiade M; van Veldhuisen DJ; Krum H; McMurray J; Lopez-Sendon J
    Clin Cardiol; 2006 Oct; 29(10):434-8. PubMed ID: 17063946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.